Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TRACON Pharmaceuticals, Inc. (TCON : NSDQ)

• Company Description    TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The company's product candidate includes TRC105, TRC205 and TRC102 which are in different clinical stage for cancer, age-related macular degeneration and fibrotic diseases. TRACON Pharmaceuticals, Inc. is headquartered in San Diego, California. Number of Employees: 19

• Price / Volume Information    Yesterday's Closing Price: $1.77 Daily Weekly Monthly 20 Day Moving Average: 90,124 shares Shares Outstanding: 20.08 (millions) Market Capitalization: $35.54 (millions) Beta: 1.82 52 Week High: $7.42 52 Week Low: $1.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.91% -12.31% 12 Week -23.71% -14.26% Year To Date -36.10% -21.94%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4350 LA JOLLA VILLAGE DRIVE SUITE 800 - San Diego,CA 92122 USA ph: 858-550-0780 fax: 858-550-0786 ir@traconpharma.com http://www.traconpharma.com

• General Corporate Information    Officers Charles P. Theuer - President and Chief Executive Officer Scott B. Brown - Chief Financial Officer William R. LaRue - Director Martin A. Mattingly - Director J. Rainer Twiford - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 89237H209 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/10/22 Share - Related Items Shares Outstanding: 20.08 Most Recent Split Date: 11.00 (0.10:1) Beta: 1.82 Market Capitalization: $35.54 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.24 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 12.74 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -45.45% vs. Previous Quarter: -20.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -292.18 12/31/21 - -182.45 09/30/21 - -132.62 ROA 03/31/22 - -125.96 12/31/21 - -97.32 09/30/21 - -78.53 Current Ratio 03/31/22 - 1.16 12/31/21 - 1.82 09/30/21 - 2.45 Quick Ratio 03/31/22 - 1.16 12/31/21 - 1.82 09/30/21 - 2.45 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -9,559.54 12/31/21 - -8,285.26 09/30/21 - -7,302.31 Book Value 03/31/22 - 0.14 12/31/21 - 0.60 09/30/21 - 0.97 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©